Eton Pharmaceuticals (ETON) Gains from Investment Securities (2018)

Eton Pharmaceuticals (ETON) posted Gains from Investment Securities of $1.5 million for Q4 2018, up 172.01% sequentially from $561000.0 in Q3 2018.

Eton Pharmaceuticals (ETON) Gains from Investment Securities (2018) Analysis & Trends

Eton Pharmaceuticals has reported Gains from Investment Securities for 1 years, with the latest figure at $1.5 million in Q4 2018.

Quarterly Gains from Investment Securities changed N/A year-over-year to $1.5 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $2.6 million (changed N/A YoY) and the FY2020 annual result came in at $226000.0, changed 0.0% from the prior year.
Gains from Investment Securities grew to $1.5 million in Q4 2018 per ETON's latest filing, from $561000.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at $1.5 million in Q4 2018 and troughed at $83000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Eton Pharmaceuticals	1.65 Bn	1.62 Bn	25.41 Mn

Download Data